Eli Lilly, FDA
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors,
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Eli Lilly weight-loss drug shortage ends, shaking up telehealth
Compounded versions of popular weight-loss drugs attracted telehealth companies that marketed services to connect patients with healthcare providers.
Inside Eli Lilly's fight against counterfeit drugs
"GMA" shares an exclusive look inside the lab of the maker of such drugs as Mounjaro and Zepbound to show what it's doing to warn users about the dangers of counterfeit drugs.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply. The FDA allows companies to produce compounded copycat drugs when the originals are hard to obtain,
Eli Lilly’s Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
GlobalData on MSN2d
NHS proposes phased launch for Eli Lilly’s Mounjaro
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
FiercePharma4d
High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
This IPO Biotech Stock Could Be the Next Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
WFYI3d
Eli Lilly announces additional $4.5 billion investment into central Indiana LEAP District
Eli Lilly announced Wednesday it will invest another $4.5 billion into a new facility at the states controversial LEAP ...
Eli Lilly to build $4.5 billion Indiana facility for advanced drug manufacturing
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...
End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...